# Surrozen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surrozen

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.surrozen.com
- Total disclosed funding: $133M
- Latest round: Series C (Jun 19, 2020)
- Investors on record: 6

## About

Surrozen, Inc. is a biotechnology company focused on leveraging Wnt biology to develop innovative regenerative therapies for various injuries and diseases. Their mission is to enhance patient recovery through advanced treatment solutions.Surrozen, Inc., founded in 2016 and headquartered in South San Francisco, US, specializes in harnessing the body’s regenerative capabilities. The firm has pivoted its strategy towards developing its proprietary Wnt biology platform. The company has secured a total of USD 50.00 mn in funding, including the most recent Series C round of USD 50.00 mn on June 19, 2020, from a mix of returning and new investors including Endowment Wealth Management and Euclidean Capital. The company was co-founded by Claudia Janda, who has a background in biotechnology, contributing to its strategic direction alongside CEO Craig Parker.Surrozen focuses on harnessing the body's regenerative capabilities to address various injuries and diseases. The company's core product offerings revolve around its innovative Wnt biology platform, which aims to stimulate tissue repair and promote regeneration in damaged organs. This platform includes SZN-043, which is currently in clinical development for treating conditions that require regenerative solutions. Surrozen primarily targets healthcare providers and pharmaceutical partners, collaborating with researchers and clinicians who seek advanced therapeutic options. The geographical markets for Surrozen's products primarily include North America and Europe, where there is a significant demand for regenerative medicine solutions to enhance patient recovery and improve outcomes in various medical settings.Surrozen's revenue model is primarily driven by partnerships and collaborations with biotech firms and healthcare institutions, leveraging its proprietary Wnt biology platform for the development of regenerative therapies. Transactions typically occur through strategic agreements that may involve research funding, milestone payments, and royalties on future product sales. The company's flagship product, SZN-043, is expected to generate revenue through agreements with pharmaceutical partners who are invested in its clinical development and market commercialization. Although specific pricing plans are not disclosed, the revenue structure is likely to include tiered pricing based on the therapeutic applications and outcomes achieved, facilitating a return on investment for users and stakeholders in the regenerative medicine sector.Surrozen plans to utilize the recent Series C funding of USD 50.00 mn to support the clinical development of its lead product SZN-043 and further enhance its Wnt biology platform. The company aims to expand its reach within the North American and European markets, focusing on strengthening collaborations with pharmaceutical partners by 2022. There are also plans to introduce additional regenerative therapies designed to address unmet medical needs, with expected launches aligned with ongoing clinical trials and partnerships.

## Funding rounds

- Series C, Jun 19, 2020, $50M — The Column Group, Horizons Ventures, Timefolio Capital, Euclidean Capital, Endowment Wealth Management, Hartford HealthCare Corporation
- Series B, Mar 14, 2019, $50M — The Column Group, Horizons Ventures, Timefolio Capital, Endowment Wealth Management, Hartford HealthCare Corporation
- Series A, Feb 15, 2017, $33M — The Column Group

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- Horizons Ventures — Series B, Series C
- Timefolio Capital — Series B, Series C
- Endowment Wealth Management (https://capitalatlas.ai/funds/endowment-wealth-management) — Series B, Series C
- Hartford HealthCare Corporation — Series B, Series C
- Euclidean Capital — Series C